We are analyzing https://link.springer.com/article/10.1007/s00345-010-0527-5.

Title:
Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer | World Journal of Urology
Description:
There is no proven, effective, standard second-line chemotherapy for castration- and docetaxel-resistant prostate cancer (DRPC). Recent data suggest that carboplatin may be effective in combination with docetaxel in this setting; however, the optimal docetaxel/carboplatin-based regimen is still unclear. We identified 43 consecutive patients with DRPC treated with carboplatin (AUC5 d1) and docetaxel (35 mg/m2 d1, 8, 15 q4w i.v.) as a second-line or subsequent salvage chemotherapy until discontinuation of therapy due to disease progression or unacceptable toxicity. Decreased prostate-specific antigen (≥50% PSA) was observed in 22/43 (51.2%, 95% CI, 35.5, 66.7%) patients, with ≥90% reduction in 12/43 patients (27.9%). At the time of analysis, the median follow-up time for all patients was 10.4 months. Median progression-free survival (PFS) for all patients was 6.5 months (95% CI 4.1, 8.9), and median overall survival (OS) was 15.8 months (95% CI 12.1, 18.5). In PSA responders, PFS was 9.5 (95% CI 8.2, 19.0) months versus 3.3 (95% CI 2.6, 4.0) months in PSA non-responders (P < 0.0001; hazard ratio (HR) 0.108) and OS was 24.4 months (95% CI 19.5, 29.4) versus 7.8 (95% CI 5.2, 10.3) months (P = 0.001; HR 0.232). Established prognostic factors were associated with survival. This regimen was reasonably well tolerated, with leukopenia/neutropenia as the most common reversible grade 3/4 toxicity (41.9/39.5%). These data suggest that weekly docetaxel plus carboplatin may be an important therapeutic second-line treatment option for patients with DRPC.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

cancer, prostate, article, google, scholar, pubmed, cas, patients, chemotherapy, oncol, docetaxel, study, castrationresistant, secondline, phase, hormonerefractory, carboplatin, clin, docetaxelresistant, therapy, months, clinical, treatment, metastatic, trials, privacy, cookies, content, data, journal, weekly, survival, access, analysis, publish, search, salvage, reuter, combination, toxicity, trial, ann, drugs, author, information, log, research, world, urology, christoph,

Topics {✒️}

castration-resistant prostate cancer docetaxel-resistant prostate cancer arnold ganser & viktor grünwald hormone-refractory prostate cancer optimal docetaxel/carboplatin-based regimen month download article/chapter androgen-independent prostate carcinoma docetaxel/carboplatin-based chemotherapy initial docetaxel-based chemotherapy prevent docetaxel-induced onycholysis 2nd/3rd line therapy martin fenner docetaxel-based therapy advanced prostate cancer progressive prostate cancer subsequent salvage chemotherapy carboplatin combination chemotherapy article world journal full article pdf related subjects prospective clinical trials recurrent prostate cancers author information authors privacy choices/manage cookies median progression-free survival salvage chemotherapy docetaxel-resistant important therapeutic drug exposure stem cell transplantation carboplatin-taxane combinations check access instant access european economic area established prognostic factors pegylated liposomal doxorubicin biweekly doxorubicin/ketoconazole regan mm testicular steroid biosynthesis carl-neuberg-str author correspondence clinical trials docetaxel-pretreated patients conditions privacy policy cytotoxic agent combinations 35 mg/m2 d1 prospective study evaluating journal finder publish phase ii trial accepting optional cookies

Questions {❓}

Michels J, Montemurro T, Murray N, Kollmannsberger C, Nguyen Chi K (2006) First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
Oh WK, Tay MH, Huang J (2007) Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?
Reid IR (2009) Osteonecrosis of the jaw: who gets it, and why?
Schertl S, Hartmann RW, Batzl-Hartmann C et al (2007) Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer
         description:There is no proven, effective, standard second-line chemotherapy for castration- and docetaxel-resistant prostate cancer (DRPC). Recent data suggest that carboplatin may be effective in combination with docetaxel in this setting; however, the optimal docetaxel/carboplatin-based regimen is still unclear. We identified 43 consecutive patients with DRPC treated with carboplatin (AUC5 d1) and docetaxel (35 mg/m2 d1, 8, 15 q4w i.v.) as a second-line or subsequent salvage chemotherapy until discontinuation of therapy due to disease progression or unacceptable toxicity. Decreased prostate-specific antigen (≥50% PSA) was observed in 22/43 (51.2%, 95% CI, 35.5, 66.7%) patients, with ≥90% reduction in 12/43 patients (27.9%). At the time of analysis, the median follow-up time for all patients was 10.4 months. Median progression-free survival (PFS) for all patients was 6.5 months (95% CI 4.1, 8.9), and median overall survival (OS) was 15.8 months (95% CI 12.1, 18.5). In PSA responders, PFS was 9.5 (95% CI 8.2, 19.0) months versus 3.3 (95% CI 2.6, 4.0) months in PSA non-responders (P < 0.0001; hazard ratio (HR) 0.108) and OS was 24.4 months (95% CI 19.5, 29.4) versus 7.8 (95% CI 5.2, 10.3) months (P = 0.001; HR 0.232). Established prognostic factors were associated with survival. This regimen was reasonably well tolerated, with leukopenia/neutropenia as the most common reversible grade 3/4 toxicity (41.9/39.5%). These data suggest that weekly docetaxel plus carboplatin may be an important therapeutic second-line treatment option for patients with DRPC.
         datePublished:2010-03-14T00:00:00Z
         dateModified:2010-03-14T00:00:00Z
         pageStart:391
         pageEnd:398
         sameAs:https://doi.org/10.1007/s00345-010-0527-5
         keywords:
            Docetaxel
            Carboplatin
            Salvage chemotherapy
            Docetaxel-resistant
            Castration-resistant
            Prostate cancer
            Urology
            Nephrology
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00345-010-0527-5/MediaObjects/345_2010_527_Fig1_HTML.gif
         isPartOf:
            name:World Journal of Urology
            issn:
               1433-8726
               0724-4983
            volumeNumber:28
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Christoph W. M. Reuter
               affiliation:
                     name:Hannover Medical School
                     address:
                        name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Michael A. Morgan
               affiliation:
                     name:Hannover Medical School
                     address:
                        name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Philipp Ivanyi
               affiliation:
                     name:Hannover Medical School
                     address:
                        name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Martin Fenner
               affiliation:
                     name:Hannover Medical School
                     address:
                        name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Arnold Ganser
               affiliation:
                     name:Hannover Medical School
                     address:
                        name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Viktor Grünwald
               affiliation:
                     name:Hannover Medical School
                     address:
                        name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer
      description:There is no proven, effective, standard second-line chemotherapy for castration- and docetaxel-resistant prostate cancer (DRPC). Recent data suggest that carboplatin may be effective in combination with docetaxel in this setting; however, the optimal docetaxel/carboplatin-based regimen is still unclear. We identified 43 consecutive patients with DRPC treated with carboplatin (AUC5 d1) and docetaxel (35 mg/m2 d1, 8, 15 q4w i.v.) as a second-line or subsequent salvage chemotherapy until discontinuation of therapy due to disease progression or unacceptable toxicity. Decreased prostate-specific antigen (≥50% PSA) was observed in 22/43 (51.2%, 95% CI, 35.5, 66.7%) patients, with ≥90% reduction in 12/43 patients (27.9%). At the time of analysis, the median follow-up time for all patients was 10.4 months. Median progression-free survival (PFS) for all patients was 6.5 months (95% CI 4.1, 8.9), and median overall survival (OS) was 15.8 months (95% CI 12.1, 18.5). In PSA responders, PFS was 9.5 (95% CI 8.2, 19.0) months versus 3.3 (95% CI 2.6, 4.0) months in PSA non-responders (P < 0.0001; hazard ratio (HR) 0.108) and OS was 24.4 months (95% CI 19.5, 29.4) versus 7.8 (95% CI 5.2, 10.3) months (P = 0.001; HR 0.232). Established prognostic factors were associated with survival. This regimen was reasonably well tolerated, with leukopenia/neutropenia as the most common reversible grade 3/4 toxicity (41.9/39.5%). These data suggest that weekly docetaxel plus carboplatin may be an important therapeutic second-line treatment option for patients with DRPC.
      datePublished:2010-03-14T00:00:00Z
      dateModified:2010-03-14T00:00:00Z
      pageStart:391
      pageEnd:398
      sameAs:https://doi.org/10.1007/s00345-010-0527-5
      keywords:
         Docetaxel
         Carboplatin
         Salvage chemotherapy
         Docetaxel-resistant
         Castration-resistant
         Prostate cancer
         Urology
         Nephrology
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00345-010-0527-5/MediaObjects/345_2010_527_Fig1_HTML.gif
      isPartOf:
         name:World Journal of Urology
         issn:
            1433-8726
            0724-4983
         volumeNumber:28
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Christoph W. M. Reuter
            affiliation:
                  name:Hannover Medical School
                  address:
                     name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Michael A. Morgan
            affiliation:
                  name:Hannover Medical School
                  address:
                     name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Philipp Ivanyi
            affiliation:
                  name:Hannover Medical School
                  address:
                     name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Martin Fenner
            affiliation:
                  name:Hannover Medical School
                  address:
                     name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Arnold Ganser
            affiliation:
                  name:Hannover Medical School
                  address:
                     name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Viktor Grünwald
            affiliation:
                  name:Hannover Medical School
                  address:
                     name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:World Journal of Urology
      issn:
         1433-8726
         0724-4983
      volumeNumber:28
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Hannover Medical School
      address:
         name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
         type:PostalAddress
      name:Hannover Medical School
      address:
         name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
         type:PostalAddress
      name:Hannover Medical School
      address:
         name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
         type:PostalAddress
      name:Hannover Medical School
      address:
         name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
         type:PostalAddress
      name:Hannover Medical School
      address:
         name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
         type:PostalAddress
      name:Hannover Medical School
      address:
         name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Christoph W. M. Reuter
      affiliation:
            name:Hannover Medical School
            address:
               name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Michael A. Morgan
      affiliation:
            name:Hannover Medical School
            address:
               name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
               type:PostalAddress
            type:Organization
      name:Philipp Ivanyi
      affiliation:
            name:Hannover Medical School
            address:
               name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
               type:PostalAddress
            type:Organization
      name:Martin Fenner
      affiliation:
            name:Hannover Medical School
            address:
               name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
               type:PostalAddress
            type:Organization
      name:Arnold Ganser
      affiliation:
            name:Hannover Medical School
            address:
               name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
               type:PostalAddress
            type:Organization
      name:Viktor Grünwald
      affiliation:
            name:Hannover Medical School
            address:
               name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
      name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
      name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
      name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
      name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
      name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(108)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.62s.

LINK . SPRINGER . COM {}